Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

New Rugged Handset Could Be A Game Changer For Siyata Mobile

First responders deserve better. Their traditional land mobile radio (LMR) setups are clunky, offer only low data speeds, and have limited coverage with dead zones that often slow down response times. Siyata Mobile Inc. ( NASDAQ: SYTA , Forum ) , with its push-to-talk ov...
Featured Submission | August 11, 2021 |

Siyata Gets Green Light from AT&T for a Slice of $100 Billion FirstNet Roll-Out

The company's pioneering technology is the first in-vehicle mobile device for FirstNet approved by AT&T. With a much-anticipated linchpin agreement with AT&T and FirstNet sealed this week, Siyata Mobile Inc. (SIM:TSX.V; SYATF:OTCQX) has catapulted itse...
Streetwise Reports | June 5, 2019 |

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...
Streetwise Reports | December 27, 2019 |

Siyata Mobile Accelerating Growth on Multiple Fronts

Expands its Global Footprint with Multiple New Contracts and a Key E-Commerce Distribution Agreement and Launches Innovative New Product Focusing on one specific niche market has long been a proven path to success. It’s also a potential road to failure if y...
Featured Submission | September 29, 2021 |

Siyata Mobile Still Bullish After Q2 Earnings Call

Earnings reports are useful for measuring financial milestones, but they don’t tell the whole story. Siyata Mobile (NASDAQ: SYTA, SYTAW) released their Q2 earnings on an October 15th call that included CEO Marc Seelenfreund, VP of Corporate Development Daniel...
Featured Submission | October 27, 2021 |

Trade war will hasten bull market for rare earths

When the Canadian prime minister or US president visits an auto plant, people are reassured that the government understands the importance of the auto sector for jobs and exports. When the Chinese president recently toured a rare earth company on home soil, it invoked fear a...
Richard (Rick) Mills | May 27, 2019 |

Trillion-dollar US infrastructure plan will draw in plenty of metal

Donald Trump appears to have torn a page from Ahead of the Herd’s manual for recharging the US economy. In an earlier article we said what the global economy really needs, in this low-growth, spending-stalled environment brought about by the pandemic, is...
Richard (Rick) Mills | June 19, 2020 |

Fate Therapeutics Shares Rise 10% as First Person Treated with Its Anti-Cancer Therapy

Shares of Fate Therapeutics traded higher after the firm reported it has treated the first patient in a first-in-human trial of FT596 for patients with B-cell malignancies and chronic lymphocytic leukemia. Clinical-stage biopharmaceutical company Fate Thera...
Streetwise Reports | April 7, 2020 |

Enochian Shares Trade Up 50% upon Concluding FDA Meeting for Potential HIV Cure

Shares of Enochian Biosciences reached a new 52-week high after the company reported that it successfully completed its FDA INTERACT meeting for ENOB-HV-01, a potential cure for HIV. Gene-modified cellular and immune therapies company Enochian Biosciences Inc. (EN...
Streetwise Reports | June 9, 2020 |

Science FACT: The Future of Food is Here…Today

Welcome to the future of food science…happening right now. CULT Food Science Corp. ( CSE.CULT , OTCQB:CULTF , Forum ) is an innovative platform advancing the future of food with an exclusive focus on cultivated meat, cultured dairy, and cell-based foods. The first...
Dave Jackson | May 4, 2022 |
1 2 3 4 5 6 7 8 9 10 ...